To Schedule An Appointment

Call 301-671-2400​

  • Home

  • Physicians

  • Patient Resources

  • Office Hours/Locations

  • Clinical Trials

  • Referring Doctors

  • Contact Us

  • More

    Mid Atlantic Retina Specialists  is a retina practice in Maryland and Pennsylvania, delivering state-of-the-art, comprehensive patient care. Our practice is dedicated to the diagnosis and treatment of retina, vitreous and macula disorders, with the goal of improving the quality of life of our patients.

    

    World-Renowned Retina Surgeons. All of our doctors are fellowship trained at outstanding institutions.

    

    Attention-to-Detail for Treatment & Surgery. Our physicians utilize the most advanced therapies and surgical approaches, combined with an unfailing attention to consistency and detail, to provide the best treatment available.

    

    Cutting Edge Technology. All of our offices have the latest diagnostic and therapeutic services. We Keep Our Patients Informed - by providing information on common diseases in print and on our website.

    Easily Accessible Offices. Our offices are easy to find, with multiple locations.

     

    To Schedule An Appointment

    Call 301-671-2400​

    Active Clinical Trials

    Diabetic Retinopathy and Diabetic Macular Edema

     

       DRCR.net Protocol W:

     

    Intravitreous Anti-VEGF Treatment for Prevention of Vision                                Threatening Diabetic Retinopathy in Eyes at High Risk

    ​

           Status: Enrolled

    ​

       DRCR.net Protocol AC:

     

    Randomized Trial of Intravitreous Aflibercept versus Intravitreous  Bevacizumab + Deferred Afliberceptf or Treatment of Central-Involved Diabetic Macular Edema

    ​

           Status: Actively enrolling

    ​

           

    Age-Related Macular Degeneration

    ​

       Dry Macular Degeneration:

    ​

    Phase III , Multi-Center, Randomized, Double-Masked, Sham –Controlled study to compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections In Patients with Geographic Atrophy secondary to Age-Related Macular Degeneration. 

    ​

    Status: Anticipated start in October, 2018

    ​

      Wet Macular Degeneration:

     

    GBV-102, long-acting depot therapy for neovascular age-related macular  degeneration.

    ​

    Status: Anticipated start in early 2019

    ​

      

    ​